Iron Deficiency Anemia Global Market Report 2025

The iron deficiency anemia market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period was driven by initiatives from non-government organizations, a rising prevalence of chronic disorders, increased focus on parental care, awareness campaigns addressing nutritional deficiencies, and the expansion of telemedicine services.

The iron deficiency anemia market size is expected to see strong growth in the next few years. It will grow to $4.55 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period is expected to be driven by an increasing focus on women's health, rising demand for minimally invasive therapies, greater availability of over-the-counter products, the expansion of distribution networks, and the growing adoption of personalized medicine. Key trends include the development of innovative drug delivery systems, advancements in diagnostic tools and monitoring devices, the emergence of combination therapies, and the integration of nanotechnology in drug delivery.

The rising prevalence of nutritional deficiencies is expected to drive the growth of the iron deficiency anemia market. Nutritional deficiency occurs when the body lacks essential nutrients such as vitamins, minerals, proteins, or fats necessary for optimal health. Poor dietary choices, the widespread consumption of processed foods, and food insecurity, particularly in lower-income populations, contribute to the increasing cases of nutritional deficiencies. Iron deficiency anemia is a common nutritional disorder in which inadequate iron intake reduces red blood cell production, impairing the body's oxygen transport capacity. For example, in December 2023, the National Health Services, a UK-based government department, reported that total hospital admissions for nutritional deficiencies in the United Kingdom doubled from 250,000 in 2021/22 to 500,000 in 2022/23. This increasing trend highlights the growing demand for iron deficiency anemia treatments.

Leading companies in the iron deficiency anemia market are focused on developing innovative solutions, such as intravenous iron injections, to enhance nutrient absorption, improve tolerance, and effectively address iron deficiency. Intravenous iron injections deliver iron directly into the bloodstream, offering a solution for patients who cannot tolerate or adequately absorb oral iron supplements. For instance, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, introduced Redshot FCM, an intravenous iron injection formulated with ferric carboxymaltose for the treatment of iron deficiency anemia (IDA). Designed for both adults and children over one year old, Redshot FCM provides a high-dose iron infusion in a single session with a strong safety profile and minimal risk of anaphylaxis. This treatment is particularly beneficial for vulnerable populations such as pregnant women, elderly individuals, and cancer patients, offering a rapid improvement in hemoglobin levels.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma AG for $11.7 billion. This acquisition aims to position CSL Limited as a global leader in iron deficiency, nephrology, and cardio-renal therapies. By integrating Vifor Pharma’s expertise, CSL expands its portfolio, strengthens its presence in high-growth markets, and enhances its focus on patient-centered care while achieving both immediate earnings growth and long-term sustainability. Vifor Pharma AG, a Switzerland-based company, is a key player in the treatment of iron deficiency and iron deficiency anemia.

Major players in the iron deficiency anemia market are AbbVie Inc., Sanofi S.A., Abbott Laboratories, Fresenius SE & Co. KGaA, Sandoz International GmbH, CSL Limited, Daiichi Sankyo Company Limited, Perrigo Company, Cipla Limited, Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Zydus Cadila, Lupin Limited, Alkem Laboratories Limited, AMAG Pharmaceuticals Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, AdvaCare Pharma LLC.

North America was the largest region in the iron deficiency anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron deficiency anemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the iron deficiency anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Iron deficiency anemia is a condition characterized by insufficient iron levels in the body, leading to inadequate production of hemoglobin, the protein in red blood cells responsible for oxygen transport. This deficiency can result from inadequate dietary intake, poor iron absorption, blood loss, or increased iron requirements, such as during pregnancy.

The primary treatment options for iron deficiency anemia include oral iron therapy, parenteral iron therapy, and red blood cell transfusion. Oral iron therapy involves the intake of iron supplements in the form of tablets, capsules, or liquids to restore iron levels in the body. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, and home healthcare providers.

The iron deficiency anemia market research report is one of a series of new reports that provides iron deficiency anemia market statistics, including iron deficiency anemia industry global market size, regional shares, competitors with an iron deficiency anemia market share, detailed iron deficiency anemia market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia industry. This iron deficiency anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The iron deficiency anemia market includes revenues earned by entities by providing services such as iron supplementation, bone marrow biopsy, complete blood count (CBC), and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.